Latest Hurler Syndrome Stories
CALABASAS, Calif., April 8, 2015 /PRNewswire/ -- ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced
SAN DIEGO, March 10, 2015 /PRNewswire/ -- ArmaGen Technologies (Calabasas, CA), a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological
Novel ZFN Genome Editing Approach Results in Sustained Levels of Enzymes Associated with Hunter, Hurler and Gaucher Syndromes RICHMOND, Calif., Feb.
CALABASAS, Calif., Dec.
ReportsnReports.com adds “Mucopolysaccharidosis I and II (MPS I & II) (Hurler Syndrome) - Pipeline Review, H2 2014” to its store.
Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ --
ArmaGen to Receive up to Approximately $225 Million Including Initial Upfront Payment of $15 Million in Cash and Equity, an Additional Equity Investment, R&D Funding, Development and Sales Milestones,
- MPS IV A patients and families urge swift, publicly funded access to life-altering drug VIMIZIM(TM) - VANCOUVER, July 7, 2014 /CNW/ - The Canadian Society for Mucopolysaccharide
Approval delivers first pharmaceutical therapy for children and adults with ultra-rare, life-limiting disorder TORONTO, July 7, 2014 /CNW/ - BioMarin Pharmaceutical Inc.
- Emitting flashes of light; glittering.